Testing a new chikungunya vaccine in healthy adults
Part of Infections clinical trials.
This study tests an experimental vaccine designed to protect against chikungunya, a mosquito-borne virus that causes fever and joint pain. The trial will evaluate the vaccine's safety and immune response in healthy adults.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 60 years old.
- You are generally healthy and have no ongoing medical conditions that could interfere with the study.
- You have not had chikungunya or other mosquito-borne diseases (like Zika or dengue) in the last 90 days.
- You have not traveled to areas where these diseases are common in the last 90 days.
- You have not received certain vaccines, including the chikungunya vaccine, within 90 days prior to the study, or other licensed vaccines within 28 days.
- You are willing to use effective birth control (if applicable) and avoid sperm donation during the study and for a period after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental chikungunya vaccine (made from a virus-like particle) to see if it prevents the disease. It is for healthy teens and adults who have not had chikungunya before.
This trial tests whether giving the dengue and chikungunya vaccines together is as safe and effective as giving them separately. If you are a healthy adult, you may be able to help find a more convenient way to protect against these diseases.
This study looks at how well the VLA1553 vaccine prevents chikungunya disease in parts of Brazil where the vaccine is being offered as part of a pilot program. If you live in one of those areas and have had symptoms that might be chikungunya, this study will use your health records and blood tests to check how effective the vaccine is.
This study follows pregnant women who received the VLA1553 vaccine (for chikungunya) to see how it affects them and their babies. It compares them to pregnant women who received a different vaccine approved during pregnancy.
This study looks at how well the chikungunya vaccine works in real life, how safe it is, and how the body's immune system responds. It is for adults who are eligible for the vaccine according to French health guidelines.
This trial tests a new treatment (PC-CHIK-V) for newborns whose mothers had chikungunya around the time of birth. The goal is to see if the treatment can prevent or reduce the infection in babies. Babies who are not treated will also be followed for comparison.
Hear when a new Chikungunya trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.